David J. Hirst

Discovery of an Orally Available Potent ER Aminopeptidase 1 (ERAP1) Inhibitor That Enhances Antitumor Responses and Limits Inflammatory Autoimmunity In Vivo

Christopher P. Tinworth, Justyna Wojno-Picon, Michael Adam, Stephan Gade et autres

gb, de, gr, fr (code pays fourni par la source)

Automated Molecular Design in BRADSHAW, Applied to the Optimization of ERAP1 Inhibitors

Robert P. Law, Ian D. Wall, Richard Lonsdale, Ross P. Hryczanek et autres

hr, gr (code pays fourni par la source)

Discovery of an orally available potent ER aminopeptidase 1 (ERAP1) inhibitor that enhances anti-tumor responses and limits inflammatory autoimmunity in vivo

Christopher P. Tinworth, Justyna Wojno-Picon, Michael J. Adam, Stephan Gade et autres

pl, gr (code pays fourni par la source)

Structure- and Property-Based Optimization of Efficient Pan-Bromodomain and Extra Terminal Inhibitors to Identify Oral and Intravenous Candidate I-BET787

David J. Hirst, Paul Bamborough, Niam Al-Mahdi, Davina C. Angell et autres

gb (code pays fourni par la source)

Identification and Optimization of a Ligand-Efficient Benzoazepinone Bromodomain and Extra Terminal (BET) Family Acetyl-Lysine Mimetic into the Oral Candidate Quality Molecule I-BET432

P. G. Humphreys, Niall A. Anderson, Paul Bamborough, Andrew Baxter et autres

gb (code pays fourni par la source)

Experimental and in silico approaches to target selection and tractability for drug discovery. Highlights from the Society for Medicines Research Conference. London – March 21, 2022

Michael M. Hann, Simon Peace, S. Skerratt, David J. Hirst et autres

Design, Synthesis, and Characterization of I-BET567, a Pan-Bromodomain and Extra Terminal (BET) Bromodomain Oral Candidate

P. G. Humphreys, Stephen J. Atkinson, Paul Bamborough, Rino A. Bit et autres

gb, cn (code pays fourni par la source)

In situ silane activation enables catalytic reduction of carboxylic acids

Emma L. Stoll, Thomas Barber, David J. Hirst, Ross M. Denton

gb (code pays fourni par la source)

GSK137, a potent small-molecule BCL6 inhibitor with in vivo activity, suppresses antibody responses in mice

Andrew C. Pearce, Mark J. Bamford, Ruth Barber, Angela Bridges et autres

gb, us (code pays fourni par la source)

A Turing Test for Molecular Generators

Jacob T. Bush, Péter Pogány, Stephen D. Pickett, Mike Barker et autres

gb, hr (code pays fourni par la source)

Structure-based optimisation of orally active & reversible MetAP-2 inhibitors maintaining a tight ‘molecular budget’

David J. Hirst, Martín Brandt, Gordon Bruton, Erica Christodoulou et autres

gb, us (code pays fourni par la source)

Hydrogen Atom Transfer‐Mediated Domino Cyclisation Reaction to Access (Spiro)Quinazolinones

Oliver Turner, David J. Hirst, John A. Murphy

gb (code pays fourni par la source)